Navigation Links
Large Study Gives Nod to Drug-Eluting Stents in Heart Attack
Date:3/30/2008

Arterial renarrowing less likely, with no increase in mortality on

long-term follow-up

CHICAGO, March 30 /PRNewswire/ -- Although drug-eluting stents have become widely used for the treatment of stable coronary artery disease, many cardiologists choose bare-metal stents for patients with heart attack, or myocardial infarction (MI), citing conflicting data about the safety and effectiveness of drug-eluting stents in this patient group. Such concerns are being challenged by an analysis of a large Massachusetts database.

The analysis showed a significantly lower risk of arterial renarrowing, or restenosis, among heart attack patients who were treated with drug-eluting stents, with no increase in mortality, when compared to those treated with bare-metal stents.

The study is being reported today in a Late-Breaking Clinical Trials session at the SCAI Annual Scientific Sessions in Partnership with ACC i2 Summit (SCAI-ACCi2) in Chicago. SCAI-ACCi2 is a scientific meeting for practicing cardiovascular interventionalists sponsored by the Society for Cardiovascular Angiography and Interventions (SCAI) in partnership with the American College of Cardiology (ACC).

"This study confirms that the same benefits that drug-eluting stents offer other patients in preventing restenosis of the coronary arteries are still there for patients with MI, and there doesn't appear to be any trade-off in increased risk of repeat MI or death," said Laura Mauri, MD, MSC, an interventional cardiologist at Brigham and Women's Hospital, an assistant professor of medicine at Harvard Medical School, and chief scientific officer at the Harvard Clinical Research Institute, all in Boston.

Cardiologists have had to decide which type of stent to use in heart attack patients based on small randomized trials that didn't include long-term follow-up and reported conflicting results. There have also been concerns that, because heart attack patients are already prone to forming blood clots in the coronary arteries, they might be at high risk for stent thrombosis, or sudden clotting inside the stent, particularly a drug-eluting stent.

To evaluate the long-term safety and effectiveness of drug-eluting stents, Dr. Mauri and her colleagues analyzed data from 7,216 patients who underwent stenting for acute MI in Massachusetts, where hospitals are required to submit data on all coronary interventions to a state database. Of these, 4,016 patients were treated with a drug-eluting stent and 3,200 were treated with a bare-metal stent. To adjust for differences in baseline risk, patients in the two groups were matched on up to 63 variables.

Researchers found that the two-year, risk-adjusted rate of revascularization -- or the need for a repeat procedure to open the coronary arteries as a result of renarrowing, or restenosis -- was significantly lower in patients treated with drug-eluting stents when compared with bare-metal stents (15.5 percent vs. 20.8 percent; p<0.001). Mortality was 10.4 percent and 13.2 percent, respectively, in the two groups (p=0.002), and repeat MI occurred in 9.5 percent and 11.0 percent, respectively (p=0.08).

"These findings are reassuring," Dr. Mauri said. "Although neither bare-metal stents nor drug-eluting stents were originally approved in the setting of acute myocardial infarction, it is probably the most important condition we treat with stents. I would feel comfortable considering drug-eluting stents on the basis of these results -- with the caveats that treated patients must be able to take antiplatelet therapy and that we definitely want to see even longer-term follow-up."

The researchers plan to continue follow-up in Massachusetts and re-examine the findings when more data are available.

Dr. Mauri will present the results of this study on Sunday, March 30 at 9:15 a.m. CDT in the Grand Ballroom, S100.

About SCAI

Headquartered in Washington, DC, the Society for Cardiovascular Angiography and Interventions is a 4,000-member professional organization representing invasive and interventional cardiologists in over 60 nations. SCAI's mission is to promote excellence in invasive and interventional cardiovascular medicine through physician education and representation, and advancement of quality standards to enhance patient care. SCAI's annual meeting has become the leading venue for education, discussion, and debate about the latest developments in this dynamic medical specialty.

About ACC

The American College of Cardiology is leading the way to optimal cardiovascular care and disease prevention. The College is a 34,000-member nonprofit medical society and bestows the credential Fellow of the American College of Cardiology upon physicians who meet its stringent qualifications. The College is a leader in the formulation of health policy, standards and guidelines, and is a staunch supporter of cardiovascular research. The ACC provides professional education and operates national registries for the measurement and improvement of quality care.


'/>"/>
SOURCE SCAI-ACCi2
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Georgia Reproductive Specialists Participates in Largest-Ever In Vitro Fertilization Clinical Trial in the World
2. Two-Year Outcomes From Large Head-to-Head Clinical Trial Indicate Similar Safety Profile in Diabetic Patients for Cypher(R) Sirolimus-Eluting Coronary Stent and Taxus Stent
3. Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER(R) Sirolimus-eluting Coronary Stent Compared to Taxus Stent
4. Large Blinded Clinical Study Achieves High Accuracy for the Diagnosis of Melanoma Using In Vivo Confocal Microscopy
5. New Data From Large Safety Analysis of MYCAMINE Shows Favorable Clinical Safety Profile
6. Isis Announces $1.2 Million Award to Its Ibis Subsidiary to Expand Influenza Detection Capabilities and Enable Large-Scale Influenza Transmission Studies
7. International Expert Group Initiates Largest Multi-center Phase III Trial to Evaluate NeuroAid(TM) in Stroke Recovery
8. Video: The Arizona Heart Institute Announces the Largest Worldwide Experience with Endoluminal Grafting to Treat Thoracic Aortic Aneurysms and Related Pathologies
9. AspenBio Pharma Reports Strong Results with Appendicitis Triage Blood Test from Large Multiple Hospital Study
10. Microarray Sequence Capture Speeds Large-Scale Resequencing of Targeted Genomic Regions
11. Large Controlled Trial of Widely Used Mood Stabilizers Demonstrates Efficacy in Pediatric Bipolar Disorder
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/28/2017)... Sept. 28, 2017 Hill-Rom Holdings, Inc. (NYSE: ... conference call and webcast on Friday, November 3, 2017, ... and ending at approximately 8:30 a.m. (CDT) / 9:30 ... company,s 2017 financial performance and guidance for 2018, Hill-Rom ... to enhance operational performance, and long-range financial outlook through ...
(Date:9/25/2017)... Sept. 25, 2017  EpiVax, Inc., a leader ... and immune-engineering today announced the launch of EpiVax ... of personalized therapeutic cancer vaccines. EpiVax has provided ... access to enabling technologies to the new precision ... lead EpiVax Oncology as Chief Executive Officer. Gad ...
(Date:9/19/2017)... , Sept. 19, 2017   ZirMed Inc ., a ... today announced that it has been ranked #1 by its ... Book™ Rankings 2017 User Survey. ZirMed was recognized as ... large hospitals and medical centers over 200 beds and holds ... healthcare technology user survey history. ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... ... While it’s often important to take certain medications during the night, finding ... identified a solution. , She developed a prototype for MOTION LIGHT-UP PILL BOX to ... the need to turn on a light when taking medication during the night, allowing ...
(Date:10/13/2017)... ... October 13, 2017 , ... PurhealthRX , a leading Health and Nutrition ... the Purzorb™process to full spectrum CBD oil will revolutionize the rapidly growing CBD market ... can be easily incorporated into liquid products, while reducing costs to end users. , ...
(Date:10/13/2017)... Shelton, CT (PRWEB) , ... October 13, 2017 , ... ... and long-term care services, staged a mock evacuation of the facility as part of ... Department, Shelton Fire Department, Echo Hose EMS and Shelton City Emergency Manager, as well ...
(Date:10/13/2017)... ... ... Ellevate Network, the leading network for professional women, brought together some of ... their inaugural Summit in New York City in June. The event was livestreamed with ... 3 million. To watch the Mobilize Women video, click here . , ...
(Date:10/13/2017)... ... ... Talented host, actor Rob Lowe, is introducing a segment ... of "Success Files," which is an award-winning educational program broadcasted on PBS Member ... with passion and integrity. , Sciatica occurs when the sciatic nerve in the ...
Breaking Medicine News(10 mins):